These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 26540320

  • 1. Should all patients with significant proteinuria take a renin-angiotensin inhibitor?
    Thomas G, Nally JV.
    Cleve Clin J Med; 2015 Nov; 82(11):716-8. PubMed ID: 26540320
    [No Abstract] [Full Text] [Related]

  • 2. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S.
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract] [Full Text] [Related]

  • 3. Inhibitors of the renin angiotensin system: proven benefits, unproven safety.
    Parfrey PS.
    Ann Intern Med; 2008 Jan 01; 148(1):76-7. PubMed ID: 17984483
    [No Abstract] [Full Text] [Related]

  • 4. Lowering asymmetric dimethylarginine--a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients?
    Kielstein JT, Fliser D.
    Blood Purif; 2007 Jan 01; 25(4):324-6. PubMed ID: 17709914
    [No Abstract] [Full Text] [Related]

  • 5. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL, Townsend RR.
    J Am Soc Nephrol; 2009 Aug 01; 20(8):1666-8. PubMed ID: 18776118
    [Abstract] [Full Text] [Related]

  • 6. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
    López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D.
    Transplant Proc; 2010 Oct 01; 42(8):2883-5. PubMed ID: 20970559
    [Abstract] [Full Text] [Related]

  • 7. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G.
    Nephrol Ther; 2010 Jan 01; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract] [Full Text] [Related]

  • 8. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep 01; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH, Luft FC.
    Kidney Int; 2006 Dec 01; 70(12):2051-3. PubMed ID: 17136130
    [Abstract] [Full Text] [Related]

  • 10. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.
    Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ.
    Hypertension; 2009 Sep 01; 54(3):e19-20. PubMed ID: 19652085
    [No Abstract] [Full Text] [Related]

  • 11. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 01; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 12. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Sealey JE, Parra D, Rosenstein R, Laragh JH.
    Hypertension; 2010 Mar 01; 55(3):e16; author reply e17. PubMed ID: 20083722
    [No Abstract] [Full Text] [Related]

  • 13. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May 01; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 14. [Antihypertensive drug therapy--combination of AT1-receptor blocker and betablocker].
    Schindler C, Kosa M, Schröder J, Kirch W.
    Dtsch Med Wochenschr; 2010 May 01; 135(3):98. PubMed ID: 20077385
    [No Abstract] [Full Text] [Related]

  • 15. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T.
    Nephrol Dial Transplant; 2008 Aug 01; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract] [Full Text] [Related]

  • 16. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 01; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 17. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V, Buksa M, Loza V, Kulic M.
    Med Arh; 2009 Jan 01; 63(6):343-9. PubMed ID: 20380117
    [Abstract] [Full Text] [Related]

  • 18. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M, Ménard J.
    Circulation; 2004 Jun 01; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract] [Full Text] [Related]

  • 19. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Jun 01; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 20. Dual renin-angiotensin system blockade: on the target.
    Robles NR.
    Int J Clin Pract; 2008 Aug 01; 62(8):1134-6. PubMed ID: 18705817
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.